vs
ADMA BIOLOGICS, INC.（ADMA）与Ranger Energy Services, Inc.（RNGR）财务数据对比。点击上方公司名可切换其他公司
Ranger Energy Services, Inc.的季度营收约是ADMA BIOLOGICS, INC.的1.0倍（$142.2M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 2.3%，领先33.2%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -0.6%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $17.1M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 1.9%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Ranger Energy Services是北美领先的陆上油田服务提供商，为上游油气运营商提供完井、修井、钻机作业及产能优化等全套解决方案，业务主要覆盖美国本土的页岩和致密资源开采作业区。
ADMA vs RNGR — 直观对比
营收规模更大
RNGR
是对方的1.0倍
$139.2M
营收增速更快
ADMA
高出19.0%
-0.6%
净利率更高
ADMA
高出33.2%
2.3%
自由现金流更多
ADMA
多$17.5M
$17.1M
两年增速更快
ADMA
近两年复合增速
1.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $142.2M |
| 净利润 | $49.4M | $3.2M |
| 毛利率 | 63.8% | — |
| 营业利润率 | 45.1% | 2.3% |
| 净利率 | 35.5% | 2.3% |
| 营收同比 | 18.4% | -0.6% |
| 净利润同比 | -55.9% | -44.8% |
| 每股收益（稀释后） | $0.20 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARNGR
| Q4 25 | $139.2M | $142.2M | ||
| Q3 25 | $134.2M | $128.9M | ||
| Q2 25 | $122.0M | $140.6M | ||
| Q1 25 | $114.8M | $135.2M | ||
| Q4 24 | $117.5M | $143.1M | ||
| Q3 24 | $119.8M | $153.0M | ||
| Q2 24 | $107.2M | $138.1M | ||
| Q1 24 | $81.9M | $136.9M |
净利润ADMARNGR
| Q4 25 | $49.4M | $3.2M | ||
| Q3 25 | $36.4M | $1.2M | ||
| Q2 25 | $34.2M | $7.3M | ||
| Q1 25 | $26.9M | $600.0K | ||
| Q4 24 | $111.9M | $5.8M | ||
| Q3 24 | $35.9M | $8.7M | ||
| Q2 24 | $32.1M | $4.7M | ||
| Q1 24 | $17.8M | $-800.0K |
毛利率ADMARNGR
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
营业利润率ADMARNGR
| Q4 25 | 45.1% | 2.3% | ||
| Q3 25 | 38.0% | 2.0% | ||
| Q2 25 | 35.1% | 6.1% | ||
| Q1 25 | 30.4% | 0.7% | ||
| Q4 24 | 32.6% | 6.2% | ||
| Q3 24 | 33.1% | 8.4% | ||
| Q2 24 | 36.6% | 5.3% | ||
| Q1 24 | 26.7% | -0.4% |
净利率ADMARNGR
| Q4 25 | 35.5% | 2.3% | ||
| Q3 25 | 27.1% | 0.9% | ||
| Q2 25 | 28.1% | 5.2% | ||
| Q1 25 | 23.4% | 0.4% | ||
| Q4 24 | 95.2% | 4.1% | ||
| Q3 24 | 30.0% | 5.7% | ||
| Q2 24 | 29.9% | 3.4% | ||
| Q1 24 | 21.7% | -0.6% |
每股收益（稀释后）ADMARNGR
| Q4 25 | $0.20 | $0.14 | ||
| Q3 25 | $0.15 | $0.05 | ||
| Q2 25 | $0.14 | $0.32 | ||
| Q1 25 | $0.11 | $0.03 | ||
| Q4 24 | $0.45 | $0.24 | ||
| Q3 24 | $0.15 | $0.39 | ||
| Q2 24 | $0.13 | $0.21 | ||
| Q1 24 | $0.08 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $10.3M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $300.1M |
| 总资产 | $624.2M | $419.3M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMARNGR
| Q4 25 | $87.6M | $10.3M | ||
| Q3 25 | $61.4M | $45.2M | ||
| Q2 25 | $90.3M | $48.9M | ||
| Q1 25 | $71.6M | $40.3M | ||
| Q4 24 | $103.1M | $40.9M | ||
| Q3 24 | $86.7M | $14.8M | ||
| Q2 24 | $88.2M | $8.7M | ||
| Q1 24 | $45.3M | $11.1M |
总债务ADMARNGR
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
股东权益ADMARNGR
| Q4 25 | $477.3M | $300.1M | ||
| Q3 25 | $431.2M | $270.0M | ||
| Q2 25 | $398.3M | $276.9M | ||
| Q1 25 | $373.4M | $272.6M | ||
| Q4 24 | $349.0M | $273.8M | ||
| Q3 24 | $231.9M | $267.6M | ||
| Q2 24 | $188.3M | $260.5M | ||
| Q1 24 | $153.7M | $261.7M |
总资产ADMARNGR
| Q4 25 | $624.2M | $419.3M | ||
| Q3 25 | $568.7M | $372.8M | ||
| Q2 25 | $558.4M | $381.7M | ||
| Q1 25 | $510.6M | $376.5M | ||
| Q4 24 | $488.7M | $381.6M | ||
| Q3 24 | $390.6M | $373.9M | ||
| Q2 24 | $376.4M | $359.6M | ||
| Q1 24 | $350.9M | $355.5M |
负债/权益比ADMARNGR
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $24.1M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $17.1M |
| 自由现金流率自由现金流/营收 | 24.8% | 12.0% |
| 资本支出强度资本支出/营收 | 0.8% | 4.9% |
| 现金转化率经营现金流/净利润 | 0.72× | 7.53× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $42.9M |
8季度趋势，按日历期对齐
经营现金流ADMARNGR
| Q4 25 | $35.6M | $24.1M | ||
| Q3 25 | $13.3M | $13.6M | ||
| Q2 25 | $21.1M | $20.7M | ||
| Q1 25 | $-19.7M | $10.6M | ||
| Q4 24 | $50.2M | $32.7M | ||
| Q3 24 | $25.0M | $17.7M | ||
| Q2 24 | $45.6M | $22.1M | ||
| Q1 24 | $-2.2M | $12.0M |
自由现金流ADMARNGR
| Q4 25 | $34.6M | $17.1M | ||
| Q3 25 | $-1.1M | $8.0M | ||
| Q2 25 | $18.7M | $14.4M | ||
| Q1 25 | $-24.4M | $3.4M | ||
| Q4 24 | $47.5M | $27.3M | ||
| Q3 24 | $24.0M | $10.8M | ||
| Q2 24 | $43.6M | $6.8M | ||
| Q1 24 | $-4.6M | $5.5M |
自由现金流率ADMARNGR
| Q4 25 | 24.8% | 12.0% | ||
| Q3 25 | -0.8% | 6.2% | ||
| Q2 25 | 15.3% | 10.2% | ||
| Q1 25 | -21.2% | 2.5% | ||
| Q4 24 | 40.4% | 19.1% | ||
| Q3 24 | 20.0% | 7.1% | ||
| Q2 24 | 40.7% | 4.9% | ||
| Q1 24 | -5.6% | 4.0% |
资本支出强度ADMARNGR
| Q4 25 | 0.8% | 4.9% | ||
| Q3 25 | 10.7% | 4.3% | ||
| Q2 25 | 2.0% | 4.5% | ||
| Q1 25 | 4.1% | 5.3% | ||
| Q4 24 | 2.3% | 3.8% | ||
| Q3 24 | 0.9% | 4.5% | ||
| Q2 24 | 1.9% | 11.1% | ||
| Q1 24 | 2.9% | 4.7% |
现金转化率ADMARNGR
| Q4 25 | 0.72× | 7.53× | ||
| Q3 25 | 0.36× | 11.33× | ||
| Q2 25 | 0.62× | 2.84× | ||
| Q1 25 | -0.73× | 17.67× | ||
| Q4 24 | 0.45× | 5.64× | ||
| Q3 24 | 0.70× | 2.03× | ||
| Q2 24 | 1.42× | 4.70× | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RNGR
| High Specification Rigs | $92.3M | 65% |
| Processing Solutions And Ancillary Services | $37.5M | 26% |
| Wireline Services | $12.4M | 9% |
